U.S. Markets open in 8 hrs 56 mins

Endo Reports Fourth-Quarter And Full Year 2018 Financial Results

DUBLIN, Feb. 28, 2019 /PRNewswire/ --

  • Fourth-quarter 2018 revenues increased 2 percent to $786 million
  • Fourth-quarter 2018 Sterile Injectables revenues increased 32 percent to $259 million
  • Fourth-quarter 2018 XIAFLEX® franchise revenues increased 30 percent to $80 million
  • Company expects 2019 revenues to range between $2.76 billion and $2.96 billion and 2019 adjusted EBITDA between $1.24 billion and $1.34 billion

Endo International plc (ENDP) today reported fourth-quarter 2018 financial results, including:

  • Revenues of $786 million, an increase of 2 percent compared to fourth-quarter 2017 revenues of $769 million; revenues increased 5 percent compared to third-quarter 2018.
  • Reported net loss from continuing operations of $265 million compared to fourth-quarter 2017 reported net loss from continuing operations of $272 million.
  • Reported diluted loss per share from continuing operations of $1.18 compared to fourth-quarter 2017 reported diluted loss per share from continuing operations of $1.22.
  • Adjusted income from continuing operations of $175 million compared to fourth-quarter 2017 adjusted income from continuing operations of $174 million.
  • Adjusted diluted EPS from continuing operations of $0.75 compared to fourth-quarter 2017 adjusted diluted EPS from continuing operations of $0.77.
  • Adjusted EBITDA of $344 million compared to fourth-quarter 2017 adjusted EBITDA of $327 million.

"We are pleased to report both revenue and adjusted EBITDA growth during the fourth quarter. This resulted from continued dedicated operational execution and strategic focus, and concluded a full year of strong performance. The fourth quarter's performance was driven by double-digit growth in our U.S. Branded - Sterile Injectables segment and in the Specialty Products portfolio of our U.S. Branded - Specialty & Established Pharmaceuticals segment," said Paul Campanelli, President and Chief Executive Officer of Endo. "We expect to further enhance our capabilities in these core growth areas as well as in the development of high-barrier generic products and we expect 2019 to be a critical transitional year as we progress to the next phase of our multi-year turnaround plan."

FINANCIAL PERFORMANCE


(in thousands, except per share amounts)



Three Months Ended December 31,




Year Ended December 31,




2018


2017


Change


2018


2017


Change

Total Revenues

$

786,389



$

768,640



2

%


$

2,947,078



$

3,468,858



(15)

%

Reported Loss from Continuing
Operations

$

(265,479)



$

(271,581)



(2)

%


$

(961,767)



$

(1,232,711)



(22)

%

Reported Diluted Weighted Average
Shares

224,353



223,322



%


223,960



223,198



%

Reported Diluted Loss per Share
from Continuing Operations

$

(1.18)



$

(1.22)



(3)

%


$

(4.29)



$

(5.52)



(22)

%

Adjusted Income from Continuing
Operations

$

175,383



$

173,863



1

%


$

663,206



$

860,361



(23)

%

Adjusted Diluted Weighted Average
Shares1

232,958



224,577



4

%


229,386



223,978



2

%

Adjusted Diluted EPS from
Continuing Operations

$

0.75



$

0.77



(3)

%


$

2.89



$

3.84



(25)

%

__________

(1)

Diluted per share data is computed based on weighted average shares outstanding and, if there is income from continuing operations during the period, the dilutive impact of share equivalents outstanding during the period. In the case of Adjusted Diluted Weighted Average Shares, Adjusted Income from Continuing Operations is used in determining whether to include such dilutive impact.


CONSOLIDATED RESULTS

Total revenues were $786 million in fourth-quarter 2018 compared to $769 million during the same period in 2017. This increase was primarily attributable to continued strong growth in the U.S. Branded - Sterile Injectables segment and the Specialty Products portfolio of our U.S. Branded - Specialty & Established Pharmaceuticals segment. In addition to the continued strong underlying performance of our core areas of growth, the fourth quarter increase in these areas reflects a benefit from the timing of shipments compared to prior year. These factors were partially offset by competitive pressures in the U.S. Generic Pharmaceuticals segment and the divestiture of the Company's Mexican business, Somar.

GAAP net loss from continuing operations in fourth-quarter 2018 was $265 million compared to GAAP net loss from continuing operations of $272 million during the same period in 2017. This result was primarily attributable to an overall reduction in operating expenses, including the impact of lower litigation-related charges and research and development expenses, partially offset by higher asset impairment charges. GAAP diluted net loss per share from continuing operations in fourth-quarter 2018 was $1.18 compared to GAAP diluted net loss per share from continuing operations of $1.22 in fourth-quarter 2017.

Adjusted income from continuing operations in fourth-quarter 2018 was $175 million compared to $174 million in fourth-quarter 2017. Adjusted diluted EPS from continuing operations in fourth-quarter 2018 was $0.75 compared to $0.77 in fourth-quarter 2017.

U.S. BRANDED - SPECIALTY & ESTABLISHED PHARMACEUTICALS

The Company reported positive results from two Phase 3 clinical trials of collagenase clostridium histolyticum (or "CCH") for the treatment of cellulite in the buttocks. Trial subjects receiving CCH showed highly statistically significant levels of improvement in the appearance of cellulite with treatment, as measured by the trial's primary endpoint.

Fourth-quarter 2018 U.S. Branded - Specialty & Established Pharmaceuticals results include:

  • Revenues of $230 million compared to $228 million in fourth-quarter 2017; this increase was primarily attributable to continued strong growth of our Specialty Products portfolio, offset by ongoing generic competition in our Established Products portfolio.
  • Specialty Products revenues increased 15 percent to $143 million in fourth-quarter 2018 compared to fourth-quarter 2017, primarily driven by the continued strong performance from XIAFLEX®. Sales of XIAFLEX® increased 30 percent to $80 million compared to fourth-quarter 2017; this increase was primarily attributable to underlying volume growth in both the Peyronie's Disease and Dupuytren's Contracture indications and a benefit from the timing of shipments compared to prior year.


U.S. BRANDED - STERILE INJECTABLES

Fourth-quarter 2018 U.S. Branded - Sterile Injectables revenues were $259 million, an increase of 32 percent compared to fourth-quarter 2017. This increase was primarily attributable to the continued strong growth of ADRENALIN® and VASOSTRICT® and a benefit from timing of shipments compared to prior year.

U.S. GENERIC PHARMACEUTICALS

During fourth-quarter 2018, the U.S. Generic Pharmaceuticals segment launched three products. Fourth-quarter 2018 U.S. Generic Pharmaceuticals revenues were $264 million compared to $303 million in fourth-quarter 2017. This performance was primarily attributable to competitive pressures in the generics business.


INTERNATIONAL PHARMACEUTICALS

Fourth-quarter 2018 International Pharmaceuticals revenues were $34 million, compared to $41 million in the same period in 2017. This performance is primarily attributable to the Somar divestiture in the fourth-quarter of 2017.

2019 FINANCIAL GUIDANCE

For the twelve months ending December 31, 2019, at current exchange rates, Endo is providing guidance on revenue, adjusted diluted EPS from continuing operations and adjusted EBITDA from continuing operations. The Company estimates:

  • Total revenues to be between $2.76 billion and $2.96 billion;
  • Adjusted diluted EPS from continuing operations to be between $2.00 and $2.25; and
  • Adjusted EBITDA from continuing operations to be between $1.24 billion and $1.34 billion.

The Company's 2019 non-GAAP financial guidance is based on the following assumptions:

  • Adjusted gross margin of approximately 65.0% to 66.0%;
  • Adjusted operating expenses as a percentage of revenues of approximately 24.5% to 25.0%;
  • Adjusted interest expense of approximately $550 million to $560 million;
  • Adjusted effective tax rate of approximately 17.5% to 18.5%;
  • Adjusted diluted weighted average shares outstanding of approximately 234 million; and
  • Revenue, Adjusted EBITDA, and Adjusted Diluted EPS weighted more towards the second half of 2019

BALANCE SHEET, LIQUIDITY AND OTHER UPDATES

As of December 31, 2018, the Company had $1.1 billion in unrestricted cash; debt of $8.3 billion; net debt of approximately $7.1 billion and a net debt to adjusted EBITDA ratio of 5.2.

Fourth-quarter 2018 cash provided by operating activities was $70 million, compared to $132 million of net cash provided by operating activities during fourth quarter 2017.

CONFERENCE CALL INFORMATION

Endo will conduct a conference call with financial analysts to discuss this press release today at 7:30 a.m. ET. The dial-in number to access the call is U.S./Canada (866) 497-0462, International (678) 509-7598, and the passcode is 8771989. Please dial in 10 minutes prior to the scheduled start time.

A replay of the call will be available from February 28, 2019 at 10:30 a.m. ET until 10:30 a.m. ET on March 3, 2019 by dialing U.S./Canada (855) 859-2056, International (404) 537-3406, and entering the passcode 8771989.

A simultaneous webcast of the call can be accessed by visiting http://investor.endo.com/events-and-presentations. In addition, a replay of the webcast will be available on the Company website for one year following the event.

FINANCIAL SCHEDULES


The following table presents Endo's unaudited Total Revenues for the three and twelve months ended December 31, 2018 and 2017 (dollars in thousands):



Three Months Ended December 31,


Percent Growth


Year Ended December 31,


Percent Growth


2018


2017



2018


2017


U.S. Branded - Specialty &
Established Pharmaceuticals:












Specialty Products:












XIAFLEX®

$

79,783



$

61,265



30

%


$

264,638



$

213,378



24

%

SUPPRELIN® LA

20,759



22,743



(9)

%


81,707



86,211



(5)

%

Other Specialty (1)

42,405



39,977



6

%


156,607



153,384



2

%

Total Specialty Products

$

142,947



$

123,985



15

%


$

502,952



$

452,973



11

%

Established Products:












PERCOCET®

$

29,362



$

32,048



(8)

%


$

122,901



$

125,231



(2)

%

VOLTAREN® Gel

13,515



15,134



(11)

%


57,700



68,780



(16)

%

OPANA® ER



1,770



(100)

%




83,826



(100)

%

Other Established (2)

44,036



55,438



(21)

%


179,279



226,715



(21)

%

Total Established Products

$

86,913



$

104,390



(17)

%


$

359,880



$

504,552



(29)

%

Total U.S. Branded - Specialty &
Established Pharmaceuticals (3)

$

229,860



$

228,375



1

%


$

862,832



$

957,525



(10)

%

U.S. Branded - Sterile Injectables:












VASOSTRICT®

$

121,380



$

99,260



22

%


$

453,767



$

399,909



13

%

ADRENALIN®

41,631



26,059



60

%


143,489



76,523



88

%

Ertapenem for injection

31,870





NM


57,668





NM

Other Sterile Injectables (4)

63,838



70,787



(10)

%


274,642



274,039



%

Total U.S. Branded - Sterile Injectables (3)

$

258,719



$

196,106



32

%


$

929,566



$

750,471



24

%

Total U.S. Generic Pharmaceuticals

$

263,770



$

302,946



(13)

%


$

1,012,215



$

1,530,530



(34)

%

Total International Pharmaceuticals

$

34,040



$

41,213



(17)

%


$

142,465



$

230,332



(38)

%

Total Revenues

$

786,389



$

768,640



2

%


$

2,947,078



$

3,468,858



(15)

%

__________

(1)

Products included within Other Specialty include NASCOBAL® Nasal Spray, TESTOPEL® and AVEED®.

(2)

Products included within Other Established include, but are not limited to, LIDODERM®, FORTESTA® Gel, EDEX® and TESTIM® including the authorized generics of TESTIM® and FORTESTA® Gel.

(3)

Individual products presented above represent the top two performing products in each product category and/or any product having revenues in excess of $100 million during any of the years ended December 31, 2018, 2017 and 2016 or $25 million during any quarterly period in 2018.

(4)

Products included within Other Sterile Injectables include, but are not limited to, APLISOL® and ephedrine sulfate injection.


 

The following table presents unaudited Condensed Consolidated Statement of Operations data for the three and twelve months ended December 31, 2018 and 2017 (in thousands, except per share data):



Three Months Ended December 31,


Year Ended December 31,


2018


2017


2018


2017

TOTAL REVENUES

$

786,389



$

768,640



$

2,947,078



$

3,468,858


COSTS AND EXPENSES:








Cost of revenues

433,214



505,645



1,631,682



2,228,530


Selling, general and administrative

167,422



161,199



646,037



629,874


Research and development

25,395



48,545



185,826



172,067


Litigation-related and other contingencies, net

(1,561)



200,006



13,809



185,990


Asset impairment charges

303,539



130,446



916,939



1,154,376


Acquisition-related and integration items

8,630



26,375



21,914



58,086


OPERATING LOSS FROM CONTINUING
OPERATIONS

$

(150,250)



$

(303,576)



$

(469,129)



$

(960,065)


INTEREST EXPENSE, NET

135,760



126,961



521,656



488,228


LOSS ON EXTINGUISHMENT OF DEBT







51,734


OTHER INCOME, NET

(18,737)



(6,180)



(51,953)



(17,023)


LOSS FROM CONTINUING OPERATIONS BEFORE
INCOME TAX

$

(267,273)



$

(424,357)



$

(938,832)



$

(1,483,004)


INCOME TAX (BENEFIT) EXPENSE

(1,794)



(152,776)



22,935



(250,293)


LOSS FROM CONTINUING OPERATIONS

$

(265,479)



$

(271,581)



$

(961,767)



$

(1,232,711)


DISCONTINUED OPERATIONS, NET OF TAX

(26,429)



(96,836)



(69,702)



(802,722)


NET LOSS

$

(291,908)



$

(368,417)



$

(1,031,469)



$

(2,035,433)


NET LOSS PER SHARE—BASIC:








Continuing operations

$

(1.18)



$

(1.22)



$

(4.29)



$

(5.52)


Discontinued operations

(0.12)



(0.43)



(0.32)



(3.60)


Basic

$

(1.30)



$

(1.65)



$

(4.61)



$

(9.12)


NET LOSS PER SHARE—DILUTED:








Continuing operations

$

(1.18)



$

(1.22)



$

(4.29)



$

(5.52)


Discontinued operations

(0.12)



(0.43)



(0.32)



(3.60)


Diluted

$

(1.30)



$

(1.65)



$

(4.61)



$

(9.12)


WEIGHTED AVERAGE SHARES:








Basic

224,353



223,322



223,960



223,198


Diluted

224,353



223,322



223,960



223,198



 

The following table presents unaudited Condensed Consolidated Balance Sheet data at December 31, 2018 and December 31, 2017 (in thousands):



December 31, 2018


December 31, 2017

ASSETS




CURRENT ASSETS:




Cash and cash equivalents

$

1,149,113



$

986,605


Restricted cash and cash equivalents

305,368



320,453


Accounts receivable

470,570



517,436


Inventories, net

322,179



391,437


Other current assets

95,920



55,146


Total current assets

$

2,343,150



$

2,271,077


TOTAL NON-CURRENT ASSETS

7,789,243



9,364,503


TOTAL ASSETS

$

10,132,393



$

11,635,580


LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY




CURRENT LIABILITIES:




Accounts payable and accrued expenses, including legal settlement accruals

$

1,914,285



$

2,184,618


Other current liabilities

35,811



36,291


Total current liabilities

$

1,950,096



$

2,220,909


LONG-TERM DEBT, LESS CURRENT PORTION, NET

8,224,269



8,242,032


OTHER LIABILITIES

456,311



687,759


SHAREHOLDERS' (DEFICIT) EQUITY

(498,283)



484,880


TOTAL LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY

$

10,132,393



$

11,635,580



 

The following table presents unaudited Condensed Consolidated Statement of Cash Flow data for the years ended December 31, 2018 and 2017 (in thousands):



Year Ended December 31,


2018


2017

OPERATING ACTIVITIES:




Net loss

$

(1,031,469)



$

(2,035,433)


Adjustments to reconcile Net loss to Net cash provided by operating activities:




Depreciation and amortization

723,707



983,765


Asset impairment charges

916,939



1,154,376


Other, including cash payments to claimants from Qualified Settlement Funds

(341,907)



451,277


Net cash provided by operating activities

$

267,270



$

553,985


INVESTING ACTIVITIES:




Purchases of property, plant and equipment, excluding capitalized interest

$

(83,398)



$

(125,654)


Proceeds from sale of business and other assets, net

70,369



223,237


Other

(4,871)



7,000


Net cash (used in) provided by investing activities

$

(17,900)



$

104,583


FINANCING ACTIVITIES:




Payments on borrowings, net

$

(39,372)



$

(22,105)


Other

(42,200)



(144,888)


Net cash used in financing activities

$

(81,572)



$

(166,993)


Effect of foreign exchange rate

(1,975)



2,515


Movement in cash held for sale



11,744


NET INCREASE IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND
RESTRICTED CASH EQUIVALENTS

$

165,823



$

505,834


CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH
EQUIVALENTS, BEGINNING OF PERIOD

1,311,014



805,180


CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH
EQUIVALENTS, END OF PERIOD

$

1,476,837



$

1,311,014



SUPPLEMENTAL FINANCIAL INFORMATION

To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures. For additional information on the Company's use of such non-GAAP financial measures, refer to Endo's Current Report on Form 8-K furnished today to the U.S. Securities and Exchange Commission, which includes an explanation of the Company's reasons for using non-GAAP measures.

The tables below provide reconciliations of certain of our non-GAAP financial measures to their most directly comparable GAAP amounts. Refer to the "Notes to the Reconciliations of GAAP and Non-GAAP Financial Measures" section below for additional details regarding the adjustments to the non-GAAP financial measures detailed throughout this Supplemental Financial Information section.

Reconciliation of EBITDA and Adjusted EBITDA (non-GAAP)


The following table provides a reconciliation of Net loss (GAAP) to Adjusted EBITDA (non-GAAP) for the three and twelve months ended December 31, 2018 and 2017 (in thousands):



Three Months Ended December 31,


Year Ended December 31,


2018


2017


2018


2017

Net loss (GAAP)

$

(291,908)



$

(368,417)



$

(1,031,469)



$

(2,035,433)


Income tax (benefit) expense

(1,794)



(152,776)



22,935



(250,293)


Interest expense, net

135,760



126,961



521,656



488,228


Depreciation and amortization (15)

167,205



177,321



688,530



857,706


EBITDA (non-GAAP)

$

9,263



$

(216,911)



$

201,652



$

(939,792)










Inventory step-up and other cost savings (2)

$



$

109



$

261



$

390


Upfront and milestone-related payments (3)

2,081



2,531



45,108



9,483


Inventory reserve increase from restructuring (4)

150



5,779



2,947



13,678


Separation benefits and other restructuring (5)

4,004



78,692



83,348



198,770


Certain litigation-related and other contingencies, net (6)

(1,561)



200,006



13,809



185,990


Asset impairment charges (7)

303,539



130,446



916,939



1,154,376


Acquisition-related and integration costs (8)

451





2,004



8,137


Fair value of contingent consideration (9)

8,179



26,375



19,910



49,949


Loss on extinguishment of debt (10)







51,734


Share-based compensation

10,349



9,897



54,071



50,149


Other income, net (16)

(18,737)



(6,180)



(51,953)



(17,023)


Other adjustments

38



(151)



(737)



(226)


Discontinued operations, net of tax (13)

26,429



96,836



69,702



802,722


Adjusted EBITDA (non-GAAP)

$

344,185



$

327,429



$

1,357,061



$

1,568,337



 

Reconciliation of Adjusted Income from Continuing Operations (non-GAAP)


The following table provides a reconciliation of our Loss from continuing operations (GAAP) to our Adjusted income from continuing operations (non-GAAP) for the three and twelve months ended December 31, 2018 and 2017 (in thousands):



Three Months Ended December 31,


Year Ended December 31,


2018


2017


2018


2017

Loss from continuing operations (GAAP)

$

(265,479)



$

(271,581)



$

(961,767)



$

(1,232,711)


Non-GAAP adjustments:








Amortization of intangible assets (1)

150,677



158,276



622,339



773,766


Inventory step-up and other cost savings (2)



109



261



390


Upfront and milestone-related payments (3)

2,081



2,531



45,108



9,483


Inventory reserve increase from restructuring (4)

150



5,779



2,947



13,678


Separation benefits and other restructuring (5)

4,004



78,692



83,348



198,770


Certain litigation-related and other contingencies, net (6)

(1,561)



200,006



13,809



185,990


Asset impairment charges (7)

303,539



130,446



916,939



1,154,376


Acquisition-related and integration costs (8)

451





2,004



8,137


Fair value of contingent consideration (9)

8,179



26,375



19,910



49,949


Loss on extinguishment of debt (10)







51,734


Other (11)

(19,034)



(7,487)



(48,942)



(8,620)


Tax adjustments (12)

(7,624)



(149,283)



(32,750)



(344,581)


Adjusted income from continuing operations (non-GAAP)

$

175,383



$

173,863



$

663,206



$

860,361



 

Reconciliation of Other Adjusted Income Statement Data (non-GAAP)


The following tables provide detailed reconciliations of various other income statement data between the GAAP and non-GAAP amounts for the three and twelve months ended December 31, 2018 and 2017 (in thousands, except per share data):



Three Months Ended December 31, 2018


Total revenues


Cost of revenues


Gross
margin


Gross margin %


Total operating expenses


Operating
expense to
revenue %


Operating
(loss)
income
from
continuing
operations


Operating margin %


Other
non-
operating
expense,
net


(Loss)
income
from
continuing
operations
before
income tax


Income
tax
(benefit)
expense


Effective tax rate


(Loss)
income
from
continuing
operations


Discontinued operations, net of tax


Net (loss) income


Diluted
(loss)
income
per share
from
continuing
operations (14)

Reported (GAAP)

$    786,389


$    433,214


$    353,175


44.9 %


$    503,425


64.0 %


$  (150,250)


(19.1)%


$ 117,023


$    (267,273)


$     (1,794)


0.7 %


$    (265,479)


$    (26,429)


$    (291,908)


$           (1.18)

Items impacting comparability:
































Amortization of intangible assets (1)


(150,677)


150,677







150,677





150,677





150,677



150,677


0.66

Upfront and milestone-related payments (3)


(741)


741




(1,340)




2,081





2,081





2,081



2,081


0.01

Inventory reserve increase from restructuring (4)


(150)


150







150





150





150



150


Separation benefits and other restructuring (5)


(30)


30




(3,974)




4,004





4,004





4,004



4,004


0.02

Certain litigation-
related and other
contingencies, net (6)






1,561




(1,561)





(1,561)





(1,561)



(1,561)


(0.01)

Asset impairment charges (7)






(303,539)




303,539





303,539





303,539



303,539


1.34

Acquisition-related and integration costs (8)






(451)




451





451





451



451


Fair value of contingent consideration (9)






(8,179)




8,179





8,179





8,179



8,179


0.04

Other (11)












19,034


(19,034)





(19,034)



(19,034)


(0.09)

Tax adjustments (12)














7,624




(7,624)



(7,624)


(0.04)

Exclude discontinued operations, net of tax (13)


















26,429


26,429


After considering items (non-GAAP)

$    786,389


$    281,616


$    504,773


64.2 %


$    187,503


23.8 %


$    317,270


40.3 %


$ 136,057


$     181,213


$      5,830


3.2 %


$     175,383


$             —


$     175,383


$            0.75


































































Three Months Ended December 31, 2017


Total revenues


Cost of revenues


Gross
margin


Gross margin %


Total operating expenses


Operating expense to revenue %


Operating
(loss)
income
from
continuing
operations


Operating margin %


Other
non-
operating
expense,
net


(Loss)
income
from
continuing
operations
before
income tax


Income
tax benefit


Effective tax rate


(Loss)
income
from
continuing
operations


Discontinued operations, net of tax


Net (loss) income


Diluted
(loss)
income
per share
from
continuing
operations (14)

Reported (GAAP)

$    768,640


$    505,645


$    262,995


34.2 %


$    566,571


73.7 %


$  (303,576)


(39.5)%


$ 120,781


$    (424,357)


$ (152,776)


36.0 %


$    (271,581)


$    (96,836)


$    (368,417)


$           (1.22)

Items impacting comparability:
































Amortization of intangible assets (1)


(158,276)


158,276







158,276





158,276





158,276



158,276


0.70

Inventory step-up and other cost savings (2)


(109)


109







109





109





109



109


Upfront and milestone-related payments (3)


(712)


712




(1,819)




2,531





2,531





2,531



2,531


0.01

Inventory reserve increase from restructuring (4)


(5,779)


5,779







5,779





5,779





5,779



5,779


0.03

Separation benefits and other restructuring (5)


(76,764)


76,764




(1,928)




78,692





78,692





78,692



78,692


0.35

Certain litigation-related and other contingencies, net (6)






(200,006)




200,006





200,006





200,006



200,006


0.90

Asset impairment charges (7)






(130,446)




130,446





130,446





130,446



130,446


0.58

Fair value of contingent consideration (9)






(26,375)




26,375





26,375





26,375



26,375


0.12

Other (11)












7,487


(7,487)





(7,487)



(7,487)


(0.03)

Tax adjustments (12)














149,283




(149,283)



(149,283)


(0.67)

Exclude discontinued operations, net of tax (13)


















96,836


96,836


After considering items (non-GAAP)

$    768,640


$    264,005


$    504,635


65.7 %


$    205,997


26.8 %


$    298,638


38.9 %


$ 128,268


$     170,370


$     (3,493)


(2.1)%


$     173,863


$             —


$     173,863


$            0.77


































































Year Ended December 31, 2018


Total revenues


Cost of revenues


Gross
margin


Gross margin %


Total operating expenses


Operating expense to revenue %


Operating
(loss)
income
from
continuing
operations


Operating margin %


Other
non-
operating
expense,
net


(Loss)
income
from
continuing
operations
before
income tax


Income
tax
expense


Effective tax rate


(Loss)
income
from
continuing
operations


Discontinued operations, net of tax


Net (loss) income


Diluted
(loss)
income
per share
from
continuing
operations (14)

Reported (GAAP)

$ 2,947,078


$ 1,631,682


$ 1,315,396


44.6 %


$ 1,784,525


60.6 %


$  (469,129)


(15.9)%


$ 469,703


$    (938,832)


$    22,935


(2.4)%


$    (961,767)


$    (69,702)


$ (1,031,469)


$           (4.29)

Items impacting comparability:
































Amortization of intangible assets (1)


(622,339)


622,339







622,339





622,339





622,339



622,339


2.77

Inventory step-up and other cost savings (2)


(261)


261







261





261





261



261


Upfront and milestone-related payments (3)


(2,836)


2,836




(42,272)




45,108





45,108





45,108



45,108


0.19

Inventory reserve increase from restructuring (4)


(2,947)


2,947







2,947





2,947





2,947



2,947


0.01

Separation benefits and other restructuring (5)


(57,487)


57,487




(25,861)




83,348





83,348





83,348



83,348


0.36

Certain litigation-related and other contingencies, net (6)






(13,809)




13,809





13,809





13,809



13,809


0.06

Asset impairment charges (7)






(916,939)




916,939





916,939





916,939



916,939


4.08

Acquisition-related and integration costs (8)






(2,004)




2,004





2,004





2,004



2,004


0.01

Fair value of contingent consideration (9)






(19,910)




19,910





19,910





19,910



19,910


0.09

Other (11)






630




(630)




48,312


(48,942)





(48,942)



(48,942)


(0.23)

Tax adjustments (12)














32,750




(32,750)



(32,750)


(0.16)

Exclude discontinued operations, net of tax (13)


















69,702


69,702


After considering items (non-GAAP)

$ 2,947,078


$    945,812


$ 2,001,266


67.9 %


$    764,360


25.9 %


$ 1,236,906


42.0 %


$ 518,015


$     718,891


$    55,685


7.7 %


$     663,206


$             —


$     663,206


$            2.89


































































Year Ended December 31, 2017


Total revenues


Cost of revenues


Gross
margin


Gross margin %


Total operating expenses


Operating expense to revenue %


Operating
(loss)
income
from
continuing
operations


Operating margin %


Other
non-
operating
expense,
net


(Loss)
income
from
continuing
operations
before
income tax


Income
tax
(benefit)
expense


Effective tax rate


(Loss)
income
from
continuing
operations


Discontinued operations, net of tax


Net (loss) income


Diluted
(loss)
income
per share
from
continuing
operations (14)

Reported (GAAP)

$ 3,468,858


$ 2,228,530


$ 1,240,328


35.8 %


$ 2,200,393


63.4 %


$  (960,065)


(27.7)%


$ 522,939


$ (1,483,004)


$ (250,293)


16.9 %


$ (1,232,711)


$  (802,722)


$ (2,035,433)


$           (5.52)

Items impacting comparability:
































Amortization of intangible assets (1)


(773,766)


773,766







773,766





773,766





773,766



773,766


3.47

Inventory step-up and other cost savings (2)


(390)


390







390





390





390



390


Upfront and milestone-related payments (3)


(2,751)


2,751




(6,732)




9,483





9,483





9,483



9,483


0.04

Inventory reserve increase from restructuring (4)


(13,678)


13,678







13,678





13,678





13,678



13,678


0.06

Separation benefits and other restructuring (5)


(162,131)


162,131




(36,639)




198,770





198,770





198,770



198,770


0.89

Certain litigation-related and other contingencies, net (6)






(185,990)




185,990





185,990





185,990



185,990


0.83

Asset impairment charges (7)






(1,154,376)




1,154,376





1,154,376





1,154,376



1,154,376


5.17

Acquisition-related and integration costs (8)






(8,137)




8,137





8,137





8,137



8,137


0.04

Fair value of contingent consideration (9)






(49,949)




49,949





49,949





49,949



49,949


0.22

Loss on extinguishment of debt (10)












(51,734)


51,734





51,734



51,734


0.23

Other (11)












8,620


(8,620)





(8,620)



(8,620)


(0.04)

Tax adjustments (12)














344,581




(344,581)



(344,581)


(1.54)

Exclude discontinued operations, net of tax (13)


















802,722


802,722


After considering items (non-GAAP)

$ 3,468,858


$ 1,275,814


$ 2,193,044


63.2 %


$    758,570


21.9 %


$ 1,434,474


41.4 %


$ 479,825


$     954,649


$    94,288


9.9 %


$     860,361


$             —


$     860,361


$            3.84

 

Notes to the Reconciliations of GAAP and Non-GAAP Financial Measures


Notes to certain line items included in the reconciliations of the GAAP financial measures to the Non-GAAP financial measures for the three and twelve months ended December 31, 2018 and 2017 are as follows:



(1)

Adjustments for amortization of commercial intangible assets included the following (in thousands):





Three Months Ended December 31,


Year Ended December 31,



2018


2017


2018


2017


Amortization of intangible assets excluding fair value
step-up from contingent consideration

$

141,917



$

148,120



$

587,932



$

733,145



Amortization of intangible assets related to fair value
step-up from contingent consideration

8,760



10,156



34,407



40,621



Total

$

150,677



$

158,276



$

622,339



$

773,766




(2)

To exclude adjustments for inventory step-up.



(3)

Adjustments for upfront and milestone-related payments to partners included the following (in thousands):





Three Months Ended December 31,



2018


2017



Cost of revenues


Operating expenses


Cost of revenues


Operating expenses


Sales-based

$

741



$



$

712



$



Development-based



1,340





1,819



Total

$

741



$

1,340



$

712



$

1,819






Year Ended December 31,



2018


2017



Cost of revenues


Operating expenses


Cost of revenues


Operating expenses


Sales-based

$

2,836



$



$

2,751



$



Development-based



42,272





6,732



Total

$

2,836



$

42,272



$

2,751



$

6,732




(4)

To exclude charges reflecting adjustments to excess inventory reserves related to our various restructuring initiatives.



(5)

Adjustments for separation benefits and other restructuring included the following (in thousands):





Three Months Ended December 31,



2018


2017



Cost of revenues


Operating expenses


Cost of revenues


Operating expenses


Separation benefits

$

17



$

(986)



$

10,087



$

1,622



Accelerated depreciation and product discontinuation
charges





63,508





Other

13



4,960



3,169



306



Total

$

30



$

3,974



$

76,764



$

1,928






Year Ended December 31,



2018


2017



Cost of revenues


Operating expenses


Cost of revenues


Operating expenses


Separation benefits

$

15,496



$

16,229



$

31,892



$

21,161



Accelerated depreciation and product discontinuation charges

35,177





123,313



398



Other

6,814



9,632



6,926



15,080



Total

$

57,487



$

25,861



$

162,131



$

36,639




(6)

To exclude litigation-related settlement charges and certain settlements proceeds related to suits filed by our subsidiaries.



(7)

Adjustments for asset impairment charges included the following (in thousands):





Three Months Ended December 31,


Year Ended December 31,



2018


2017


2018


2017


Goodwill impairment charges

$

289,000



$



$

680,000



$

288,745



Other intangible asset impairment charges

12,842



125,778



230,418



799,955



Property, plant and equipment impairment charges

1,697



4,668



6,521



65,676



Total asset impairment charges

$

303,539



$

130,446



$

916,939



$

1,154,376




(8)

Adjustments for acquisition and integration items primarily relate to various acquisitions.



(9)

To exclude the impact of changes in the fair value of contingent consideration resulting from changes to our estimates regarding the timing and amount of the future revenues of the underlying products and changes in other assumptions impacting the probability of, and extent to which we will incur related contingent obligations.



(10)

To exclude the loss on the extinguishment of debt associated with our April 2017 refinancing.



(11)

Other adjustments included the following (in thousands):





Three Months Ended December 31,



2018


2017



Operating expenses


Other non-operating expenses


Operating expenses


Other non-operating expenses


Foreign currency impact related to the re-measurement
of intercompany debt instruments

$



$

(3,926)



$



$

1,519



(Gain) loss on sale of business and other assets



(15,513)





(8,931)



Other miscellaneous



405





(75)



Total

$



$

(19,034)



$



$

(7,487)






Year Ended December 31,



2018


2017



Operating expenses


Other non-operating expenses


Operating expenses


Other non-operating expenses


Foreign currency impact related to the re-measurement of intercompany debt instruments

$



$

(5,486)



$



$

(1,403)



(Gain) loss on sale of business and other assets



(39,527)





(8,931)



Other miscellaneous

(630)



(3,299)





1,714



Total

$

(630)



$

(48,312)



$



$

(8,620)




(12)

Adjusted income taxes are calculated by tax effecting adjusted pre-tax income and permanent book-tax differences at the applicable effective tax rate that will be determined by reference to statutory tax rates in the relevant jurisdictions in which the Company operates. Adjusted income taxes include current and deferred income tax expense commensurate with the non-GAAP measure of profitability.



(13)

To exclude the results of the businesses reported as discontinued operations, net of tax.



(14)

Calculated as Net (loss) income from continuing operations divided by the applicable weighted average share number. The applicable weighted average share numbers are as follows (in thousands):





Three Months Ended December 31,


Year Ended December 31,



2018


2017


2018


2017


GAAP EPS


224,353




223,322




223,960




223,198



Non-GAAP EPS


232,958




224,577




229,386




223,978




(15)

Depreciation and amortization per the Adjusted EBITDA reconciliations do not include certain depreciation amounts reflected in other lines of the reconciliations, including Acquisition-related and integration costs and Separation benefits and other restructuring.



(16)

To exclude Other income, net per the Consolidated Statement of Operations.

 

Reconciliation of Net Debt Leverage Ratio (non-GAAP)


The following table provides a reconciliation of our Net loss (GAAP) to our Adjusted EBITDA (non-GAAP) for the twelve months ended December 31, 2018 (in thousands) and the calculation of our Net Debt Leverage Ratio (non-GAAP):



Twelve Months
Ended December
31, 2018

Net loss (GAAP)

$

(1,031,469)


Income tax expense

22,935


Interest expense, net

521,656


Depreciation and amortization (15)

688,530


EBITDA (non-GAAP)

$

201,652




Inventory step-up and other cost savings

$

261


Upfront and milestone-related payments

45,108


Inventory reserve increase from restructuring

2,947


Separation benefits and other restructuring

83,348


Certain litigation-related and other contingencies, net

13,809


Asset impairment charges

916,939


Acquisition-related and integration costs

2,004


Fair value of contingent consideration

19,910


Loss on extinguishment of debt


Share-based compensation

54,071


Other income, net

(51,953)


Other adjustments

(737)


Discontinued operations, net of tax

69,702


Adjusted EBITDA (non-GAAP)

$

1,357,061




Calculation of Net Debt:


Debt

$

8,258,419


Cash (excluding Restricted Cash)

1,149,113


Net Debt (non-GAAP)

$

7,109,306




Calculation of Net Debt Leverage:


Net Debt Leverage Ratio (non-GAAP)

5.2



Non-GAAP Financial Measures

The Company utilizes certain financial measures that are not prescribed by or prepared in accordance with accounting principles generally accepted in the U.S. (GAAP). These Non-GAAP financial measures are not, and should not be viewed as, substitutes for GAAP net income and its components and diluted earnings per share amounts. Despite the importance of these measures to management in goal setting and performance measurement, we stress that these are Non-GAAP financial measures that have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, Non-GAAP adjusted EBITDA and Non-GAAP adjusted net income from continuing operations and its components (unlike GAAP net income from continuing operations and its components) may not be comparable to the calculation of similar measures of other companies. These Non-GAAP financial measures are presented solely to permit investors to more fully understand how management assesses performance.

Investors are encouraged to review the reconciliations of the non-GAAP financial measures used in this press release to their most directly comparable GAAP financial measures. However, the Company does not provide reconciliations of projected non-GAAP financial measures to GAAP financial measures, nor does it provide comparable projected GAAP financial measures for such projected non-GAAP financial measures. The Company is unable to provide such reconciliations without unreasonable efforts due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, including adjustments that could be made for asset impairments, contingent consideration adjustments, legal settlements, loss on extinguishment of debt, adjustments to inventory and other charges reflected in the reconciliation of historic numbers, the amount of which could be significant.

See Endo's Current Report on Form 8-K furnished today to the U.S. Securities and Exchange Commission for an explanation of Endo's non-GAAP financial measures.

About Endo International plc

Endo International plc (ENDP) is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients in need through excellence in development, manufacturing and commercialization. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA. Learn more at www.endo.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including but not limited to the statements by Mr. Campanelli, as well as other statements regarding product development, market potential, corporate strategy, optimization efforts and restructurings, timing, closing and expected benefits and value from any acquisition, expected growth and regulatory approvals, together with Endo's earnings per share from continuing operations amounts, product net sales, revenue forecasts and any other statements that refer to Endo's expected, estimated or anticipated future results. Because forecasts are inherently estimates that cannot be made with precision, Endo's performance at times differs materially from its estimates and targets, and Endo often does not know what the actual results will be until after the end of the applicable reporting period. Therefore, Endo will not report or comment on its progress during a current quarter except through public announcement. Any statement made by others with respect to progress during a current quarter cannot be attributed to Endo.

All forward-looking statements in this press release reflect Endo's current analysis of existing trends and information and represent Endo's judgment only as of the date of this press release. Actual results may differ materially from current expectations based on a number of factors affecting Endo's businesses, including, among other things, the following: changing competitive, market and regulatory conditions; changes in legislation; Endo's ability to obtain and maintain adequate protection for its intellectual property rights; the timing and uncertainty of the results of both the research and development and regulatory processes, including regulatory decisions, product recalls, withdrawals and other unusual items; domestic and foreign health care and cost containment reforms, including government pricing, tax and reimbursement policies; technological advances and patents obtained by competitors; the performance, including the approval, introduction, and consumer and physician acceptance of new products and the continuing acceptance of currently marketed products; the effectiveness of advertising and other promotional campaigns; the timely and successful implementation of strategic initiatives; the timing or results of any pending or future litigation, investigations or claims or actual or contingent liabilities, settlement discussions, negotiations or other adverse proceedings; unfavorable publicity regarding the misuse of opioids; timing and uncertainty of any acquisition, including the possibility that various closing conditions may not be satisfied or waived, uncertainty surrounding the successful integration of any acquired business and failure to achieve the expected financial and commercial results from such acquisition; the uncertainty associated with the identification of and successful consummation and execution of external corporate development initiatives and strategic partnering transactions; and Endo's ability to obtain and successfully maintain a sufficient supply of products to meet market demand in a timely manner. In addition, U.S. and international economic conditions, including higher unemployment, political instability, financial hardship, consumer confidence and debt levels, taxation, changes in interest and currency exchange rates, international relations, capital and credit availability, the status of financial markets and institutions, fluctuations or devaluations in the value of sovereign government debt, as well as the general impact of continued economic volatility, can materially affect Endo's results. Therefore, the reader is cautioned not to rely on these forward-looking statements. Endo expressly disclaims any intent or obligation to update these forward-looking statements except as required to do so by law.

Additional information concerning the above-referenced risk factors and other risk factors can be found in press releases issued by Endo, as well as Endo's public periodic filings with the U.S. Securities and Exchange Commission and with securities regulators in Canada, including the discussion under the heading "Risk Factors" in Endo's most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. Copies of Endo's press releases and additional information about Endo are available at www.endo.com or you can contact the Endo Investor Relations Department by calling 845-364-4833.

Cision

View original content:http://www.prnewswire.com/news-releases/endo-reports-fourth-quarter-and-full-year-2018-financial-results-300803791.html